

Biocon Biologics Finland OY
BALANCE SHEET AS AT MARCH 31, 2025

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31,</u> <u>2025</u>	<u>March 31,</u> <u>2024</u>
ASSETS			
Current assets			
Financial assets			
(i) Trade receivables	1	452	219
(ii) Cash and cash equivalents	2	233	70
Other current assets	3	43	4
Total current assets		728	293
TOTAL		728	293
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4	-	-
Other equity	5	46	9
Total equity		46	9
Current liabilities			
Financial liabilities			
(i) Trade payables	6	589	159
(ii) Other financial liabilities			
Income-tax liability (net)		12	-
Provisions	7	73	98
Other current liabilities	8	8	27
Total current liabilities		682	284
TOTAL		728	293

Biocon Biologics Finland OY**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	Year ended March 31, 2025	Period ended March 31, 2024
Income			
Revenue from operations	9	961	-
Other operating income	10	12	399
Total revenue		973	399
Expenses			
Purchases of traded goods	11	(32)	-
Employee benefits expense	12	536	230
Other expenses	13	423	158
Total expenses		927	388
Profit before tax		46	11
Tax expense			
Current tax		3	2
Deferred Tax		6	-
Total tax expense		9	2
Profit for the year		37	9

Biocon Biologics Finland OY**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2025	Period ended March 31, 2024
I Cash flows from operating activities		
Profit after tax	37	10
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Unrealised foreign exchange loss	12	-
Tax expense	9	3
Operating profit before working capital changes	58	13
Movements in working capital		
(Increase) in trade receivables	(233)	(208)
(Increase) in loans and advances and other assets	(39)	(8)
Increase in trade payable, other liabilities and provisions	389	273
Cash generated generated from operations	175	70
Direct taxes paid	-	-
Net cash flow generated from operating activities	175	70
II Net increase/(decrease) in cash and cash equivalents	175	70
III Effect of exchange differences on cash and cash equivalents held in foreign currency	(12)	-
IV Cash and cash equivalents at the beginning of the year	70	-
V Cash and cash equivalents at the end of the year (II + III + IV)	233	70
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	233	70
Cash on hand	-	-
Total cash and cash equivalents [Refer note 2]	233	70

Biocon Biologics Finland OY**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2025	March 31, 2024
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	452	209
Other receivables	-	10
	452	219
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	233	70
	233	70
3. Other current assets		
Prepayments	6	4
Balance with Government Authorities	37	-
	43	4
4. Share capital		
Equity share 1 Common stock of EUR 0 each	-	-
	-	-
5. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	9	-
Profit for the year	37	9
Net surplus in the statement of profit and loss	46	9
Total other equity	46	9
6. Trade payables	589	159
7. Provisions		
Current		
Compensated absences	69	98
	69	98
8. Other liabilities		
Current liabilities		
Statutory liabilities	8	27
	8	27

Biocon Biologics Finland OY**Notes to financial statements for the year ended March 31, 2025**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Period ended March 31, 2024
9. Revenue from operations		
Sale of Services		
Support service cross charge to Group Companies	961	-
	961	-
10. Other operating income		
Foreign exchange fluctuations, net	12	-
Support service cross charge to Group Companies	-	399
	12	399
11. Purchase of traded goods	(32)	-
	(32)	-
12. Employee benefits expense		
Salaries, wages and bonus	521	230
Staff welfare expenses	15	-
	536	230
13. Other expenses		
Rates and taxes	26	-
Rent	2	4
Legal and professional fees	139	105
Repair and Maintenance	20	2
Research and development expenses	1	-
Travelling and conveyance	86	25
Sales promotion expenses	86	16
Printing and stationery	10	5
Communication expenses	2	1
Miscellaneous expenses	51	-
	423	158